[go: up one dir, main page]

MX2020014163A - Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. - Google Patents

Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Info

Publication number
MX2020014163A
MX2020014163A MX2020014163A MX2020014163A MX2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A
Authority
MX
Mexico
Prior art keywords
solid forms
ynoyl
pyrazin
imidazo
pyrrolidin
Prior art date
Application number
MX2020014163A
Other languages
English (en)
Inventor
Fritz Blatter
Jerry Evarts
Tjeerd Barf
Tim Ingallinera
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020014163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2020014163A publication Critical patent/MX2020014163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)

Abstract

En algunas modalidades, la invención se refiere a formas sólidas cristalinas, incluyendo polimorfos, hidratos y formas de sal, de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pi razin-1-il)-N-(piridin-2-il)benzamida. En algunas modalidades, la invención también se refiere a composiciones farmacéuticas que contienen las formas sólidas cristalinas, y a métodos para tratar afecciones o trastornos administrando a un sujeto una composición farmacéutica que incluye las formas, incluyendo composiciones farmacéuticas y métodos para superar los efectos de los agentes reductores de ácido. Fórmula (I). (ver Fórmula).
MX2020014163A 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. MX2020014163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
PCT/IB2016/053988 WO2017002095A1 (en) 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number Publication Date
MX2020014163A true MX2020014163A (es) 2022-09-29

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020014163A MX2020014163A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
MX2018000179A MX378495B (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018000179A MX378495B (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida.

Country Status (29)

Country Link
US (7) US9796721B2 (es)
EP (4) EP3613745B1 (es)
JP (3) JP6829215B2 (es)
KR (2) KR102688052B1 (es)
CN (2) CN108349978B (es)
AU (3) AU2016286548B2 (es)
CA (1) CA2991096A1 (es)
CL (1) CL2017003445A1 (es)
CY (3) CY1124519T1 (es)
DK (3) DK3317281T3 (es)
ES (3) ES2946489T3 (es)
FI (2) FI4209493T3 (es)
HR (3) HRP20211511T1 (es)
HU (3) HUE062258T2 (es)
IL (3) IL293821A (es)
LT (4) LT3954690T (es)
MA (2) MA64013B1 (es)
MD (1) MD3317281T2 (es)
MX (2) MX2020014163A (es)
MY (1) MY193514A (es)
PL (3) PL3317281T3 (es)
PT (4) PT3954690T (es)
RS (3) RS64195B1 (es)
RU (1) RU2018103913A (es)
SG (1) SG10201913796UA (es)
SI (3) SI3954690T1 (es)
SM (3) SMT202100597T1 (es)
WO (1) WO2017002095A1 (es)
ZA (2) ZA201800329B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62713B1 (sr) * 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
JP6829215B2 (ja) 2015-07-02 2021-02-10 アセルタ ファーマ ビー．ブイ． （Ｓ）−４−（８−アミノ−３−（１−（ブト−２−イノイル）ピロリジン−２−イル）イミダゾ［１，５−ａ］ピラジン−１−イル）−Ｎ−（ピリジン−２−イル）ベンザミドの固体形態及び製剤
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
WO2018064797A1 (zh) * 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
WO2018148961A1 (zh) * 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
CA3073293A1 (en) 2017-08-29 2019-03-07 Apotex Inc. Novel crystalline forms of acalabrutinib
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019105359A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Acalabrutinib的晶型及其制备方法和用途
WO2019134455A1 (zh) 2018-01-05 2019-07-11 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
CN110650960B (zh) * 2018-04-26 2021-08-24 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
IL281025B2 (en) 2018-08-29 2024-12-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
WO2020065667A1 (en) 2018-09-25 2020-04-02 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
WO2020198429A1 (en) 2019-03-27 2020-10-01 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
US12534467B2 (en) 2019-12-02 2026-01-27 Natco Pharma Limited Process for the preparation of Acalabrutinib
WO2021135346A1 (zh) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
WO2021239893A1 (en) 2020-05-29 2021-12-02 Bend Research, Inc. Amorphous solid dispersion of acalabrutinib
PE20230992A1 (es) * 2020-06-19 2023-06-23 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
WO2022153330A1 (en) * 2021-01-13 2022-07-21 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) * 2022-04-19 2023-10-26 The Johns Hopkins University Improved raman spectroscopy with the addition of aromatic compounds
WO2024164066A1 (en) * 2023-02-09 2024-08-15 Apotex Inc Crystalline forms of acalabrutinib maleate
WO2025125383A1 (en) 2023-12-11 2025-06-19 Synthon B.V. Crystalline forms of acalabrutinib hydrogen maleate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP2003509427A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療剤としてのキナーゼ阻害剤
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
RU2405784C2 (ru) 2003-10-15 2010-12-10 Оси Фармасьютикалз, Инк. Имидазопиразины в качестве ингибиторов тирозинкиназ
CN1960993A (zh) 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
KR101655455B1 (ko) 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
NZ569050A (en) 2005-11-17 2010-11-26 Osi Pharm Inc Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2954900A1 (en) 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
RU2010128239A (ru) 2007-12-13 2012-01-20 Новартис АГ (CH) Комбинации терапевтических средств, предназначенных для лечения рака
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
MX2012009208A (es) 2010-02-08 2012-09-07 Msd Oss Bv Compuestos de 8-metil-1-fenil-imidazol[1, 5-a]pirazina.
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
CA2841887A1 (en) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
ES2950569T3 (es) * 2011-07-19 2023-10-11 Merck Sharp & Dohme (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013174876A1 (en) * 2012-05-23 2013-11-28 Nerviano Medical Sciences S.R.L. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
CN105073115A (zh) 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
ES2708350T3 (es) 2013-04-08 2019-04-09 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas para el tratamiento de linfomas
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
WO2015086642A1 (en) 2013-12-13 2015-06-18 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
JP6829215B2 (ja) * 2015-07-02 2021-02-10 アセルタ ファーマ ビー．ブイ． （Ｓ）−４−（８−アミノ−３−（１−（ブト−２−イノイル）ピロリジン−２−イル）イミダゾ［１，５−ａ］ピラジン−１−イル）−Ｎ−（ピリジン−２−イル）ベンザミドの固体形態及び製剤

Also Published As

Publication number Publication date
SI3317281T1 (sl) 2020-08-31
US10167291B2 (en) 2019-01-01
CY1124815T1 (el) 2022-11-25
ES2895802T3 (es) 2022-02-22
EP3317281B1 (en) 2020-04-22
HUE049989T2 (hu) 2020-11-30
LT4209493T (lt) 2026-01-26
KR102688052B1 (ko) 2024-07-25
CL2017003445A1 (es) 2018-05-11
MA64013B1 (fr) 2026-01-30
LT3954690T (lt) 2023-05-25
JP2021073235A (ja) 2021-05-13
IL256633A (en) 2018-02-28
HUE056008T2 (hu) 2022-01-28
CN113480542A (zh) 2021-10-08
US20240199622A1 (en) 2024-06-20
CY1124519T1 (el) 2022-03-24
US20220177476A1 (en) 2022-06-09
ES2797987T3 (es) 2020-12-04
CY1126103T1 (el) 2023-11-15
EP3954690B1 (en) 2023-04-05
IL274066B (en) 2022-07-01
US20180208596A1 (en) 2018-07-26
US11059829B2 (en) 2021-07-13
FI4209493T3 (fi) 2026-01-19
US20220348582A1 (en) 2022-11-03
CA2991096A1 (en) 2017-01-05
US10640509B2 (en) 2020-05-05
US9796721B2 (en) 2017-10-24
CN113480542B (zh) 2025-07-25
AU2022291635A1 (en) 2023-02-02
AU2016286548B2 (en) 2020-12-10
SMT202300165T1 (it) 2023-07-20
LT3317281T (lt) 2020-07-27
PL3954690T3 (pl) 2023-08-14
IL274066A (en) 2020-06-30
DK3317281T3 (da) 2020-06-15
RS62455B1 (sr) 2021-11-30
DK3613745T3 (da) 2021-10-18
JP2018522877A (ja) 2018-08-16
RU2018103913A3 (es) 2019-12-31
RS60411B1 (sr) 2020-07-31
LT3613745T (lt) 2021-10-11
US20170029428A1 (en) 2017-02-02
SMT202100597T1 (it) 2021-11-12
RS64195B1 (sr) 2023-06-30
ES2946489T3 (es) 2023-07-19
HK1250511A1 (en) 2018-12-21
JP7091494B2 (ja) 2022-06-27
EP4209493B1 (en) 2025-11-12
HRP20230417T1 (hr) 2023-07-07
PL3317281T3 (pl) 2020-11-02
US20200255437A1 (en) 2020-08-13
ZA202000300B (en) 2022-03-30
PT3613745T (pt) 2021-10-14
SMT202000304T1 (it) 2020-07-08
CN108349978B (zh) 2021-07-23
MA50817A (fr) 2021-04-21
IL293821A (en) 2022-08-01
SI3954690T1 (sl) 2023-07-31
SI3613745T1 (sl) 2021-12-31
KR20240115937A (ko) 2024-07-26
PL3613745T3 (pl) 2022-01-31
JP2022120156A (ja) 2022-08-17
IL256633B (en) 2020-05-31
MY193514A (en) 2022-10-17
FI3954690T3 (fi) 2023-05-31
JP6829215B2 (ja) 2021-02-10
US20190337949A1 (en) 2019-11-07
AU2016286548A1 (en) 2018-02-01
SG10201913796UA (en) 2020-03-30
EP3317281A1 (en) 2018-05-09
WO2017002095A1 (en) 2017-01-05
ZA201800329B (en) 2022-04-28
EP3613745B1 (en) 2021-09-01
PT3954690T (pt) 2023-06-06
KR20180048593A (ko) 2018-05-10
MA50817B1 (fr) 2021-10-29
US11820777B2 (en) 2023-11-21
MX378495B (es) 2025-03-11
AU2020277123B2 (en) 2022-09-29
EP4209493A1 (en) 2023-07-12
RU2018103913A (ru) 2019-08-02
MX2018000179A (es) 2018-06-27
DK3954690T3 (da) 2023-06-06
MD3317281T2 (ro) 2020-07-31
PT3317281T (pt) 2020-06-18
EP3613745A1 (en) 2020-02-26
AU2020277123A1 (en) 2020-12-24
EP3954690A1 (en) 2022-02-16
AU2022291635B2 (en) 2024-06-27
PT4209493T (pt) 2026-01-08
HRP20200934T1 (hr) 2020-09-18
CN108349978A (zh) 2018-07-31
HRP20211511T1 (hr) 2021-12-24
HUE062258T2 (hu) 2023-10-28

Similar Documents

Publication Publication Date Title
MX2020014163A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
NZ708593A (en) Novel pyrazole derivative
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
GB201104267D0 (en) Pyrrolopyridineamino derivatives
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
IN2014KN00849A (es)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.